$17.40 $0.10 per serving
Product analysis
Liquid D-3 & MK-7 combines vitamin D for calcium absorption with MK-7 for normal bone-protein function. Its focused formula and low serving cost make it appealing for filling those nutrient gaps.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality66
MK-7 is specifically identified, matching the vitamin K preparation behind the relevant bone-protein findings. The vitamin D is described as lanolin sourced, but its comparative source quality remains uncertain.
Ingredient Transparency100
Both vitamin amounts and source descriptions are stated. The simple combination avoids undisclosed mixture proportions.
Value For Money66
The MK-7 contribution offers favorable value at the low serving cost. A separate vitamin D value comparison is unavailable.
Customer Satisfaction91
Customer ratings indicate high satisfaction. Thousands of ratings provide a broad feedback base.
Product Focus77
Bone and mineral nutrition is the clearest purpose for the two-vitamin combination. The MK-7 amount is below one favorable long-term trial exposure, and wider benefits depend on preparation and user context.
- Format
Liquid - Container
- 1 Liquid(s)
- Per serving
- $0.10
- Customer rating
- 4.8 · 5,143 ratings
Goals
Impact
Highest effect
Vitamin K · 100 mcgVitamin D · 62.5 mcg
Vitamin D supports calcium absorption and deficiency-related bone mineralization, while MK-7 vitamin K helps activate bone proteins. MK-7 has limited long-term bone-density evidence in postmenopausal women, with inconsistent findings across trials and no established general fracture protection. This serving supplies 100 mcg MK-7, below the 180 mcg daily amount in one favorable trial. The higher vitamin D amount does not establish extra fracture benefit in generally healthy adults.
How this product is rated for Bone Health
Ingredient fit85
Both ingredients relate directly to bone regulation, with stronger saved amount support for vitamin D than for MK-7.
Goal fit
The two-ingredient formula is focused on bone-related vitamin functions, though linked to several goals.
Dose adequacy
Vitamin D receives full amount support; 100 mcg MK-7 provides partial support relative to the supplied long-term trial amount.
Pathways80
Calcium regulation is the strongest route, with additional bone-protein activation through MK-7. The formula does not supply bone minerals.
Depth
Vitamin D makes calcium absorption and regulation the strongest route.
Breadth
Calcium regulation and bone-protein activation reach the coverage threshold.
Evidence98
MK-7 leads the saved evidence ranking, with preparation-specific and population-specific limitations.
Evidence strength
MK-7 leads the saved ranking, but its bone-density findings do not establish general fracture prevention.
Studied preparation
Both preparations are recognized, including the explicitly identified MenaQ7 MK-7 identity; branding adds no separate benefit.
Formulation logic92
Vitamin D lacks its designated calcium partner, while MK-7 contributes independently. No evaluated conflict was found.
Partner coverage
Calcium is absent as vitamin D's designated partner.
Conflicts
No evaluated ingredient conflict was identified.
Effective doses
Both vitamins reach the qualifying amount threshold.
Impact
Highest effect
Vitamin D · 62.5 mcgVitamin K · 100 mcg
Vitamins D and K contribute to nutrient availability associated with bone and mineral metabolism. They can help fill dietary gaps, but the supplied facts do not establish cardiovascular protection or additional benefit from combining them. Vitamin D meets the saved amount comparison, while vitamin K receives partial recognition.
How this product is rated for Everyday Health
Ingredient fit84
Vitamin D and K provide the recognized nutritional fit. Vitamin D meets the comparison; the 100 mcg vitamin K serving receives partial recognition.
Goal fit
Vitamin D and K provide the recognized nutritional fit.
Dose adequacy
Vitamin D meets the comparison; the 100 mcg vitamin K serving receives partial recognition.
Pathways60
Bone and mineral metabolism leads, with lesser antioxidant and immune coverage.
Depth
Bone and mineral metabolism leads, with lesser antioxidant and immune coverage.
Breadth
One nutrient-related pathway reaches the breadth threshold.
Evidence82
Vitamin D drives the strongest recognized contribution. Nutrient availability supports the finding; D/K combination benefit and form superiority are not established.
Evidence strength
Vitamin D drives the strongest recognized contribution. Nutrient availability supports the finding; D/K combination benefit and form superiority are not established.
Studied preparation
The counted nutrient declarations match the saved preparation criteria; no chemical form or delivery superiority is established.
Formulation logic100
No configured formulation conflict was matched. All ingredients included in this amount check meet the saved minimum threshold; that does not establish a clinically effective dose.
Partner coverage
Recognized ingredients can stand alone or have their required partners; this does not establish an added combination benefit.
Conflicts
No configured formulation conflict was matched.
Effective doses
All ingredients included in this amount check meet the saved minimum threshold; that does not establish a clinically effective dose.
Impact
High effect
Vitamin K · 100 mcgVitamin D · 62.5 mcg
MK-7 vitamin K has limited evidence relating to arterial stiffness, based on specific preparations and populations. This does not establish prevention of cardiovascular events. The supplied vitamin D has no established routine cardiovascular prevention benefit, and the combination does not establish an added benefit.
How this product is rated for Heart Health
Ingredient fit82
MK-7 vitamin K provide the relevant ingredient contributions. The declared amounts contribute according to their separate saved references.
Goal fit
MK-7 vitamin K are relevant to this goal; the formula's other actives and wider uses affect how focused it is.
Dose adequacy
The relevant ingredients contribute differently according to their declared amounts and preparation-specific references.
Pathways19
MK-7 vitamin K provide the strongest saved contribution through arterial calcification control. No route reaches the saved coverage threshold despite a partial contribution.
Depth
MK-7 vitamin K provide the strongest saved contribution through arterial calcification control.
Breadth
No route reaches the saved coverage threshold despite a partial contribution.
Evidence77
MK-7 provides the strongest saved evidence contribution, limited to arterial-stiffness measures in specific populations.
Evidence strength
MK-7 provides the strongest saved evidence contribution, limited to arterial-stiffness measures in specific populations.
Studied preparation
The ingredients with qualifying amounts meet the saved preparation criteria; this does not establish finished-product efficacy or form superiority.
Formulation logic100
The contributing ingredients meet the saved minimum amount and partner conditions. No configured conflict was identified.
Partner coverage
The contributing ingredients work independently or have their required partners in the supplied findings.
Conflicts
No configured ingredient conflict was identified in the supplied facts.
Effective doses
All ingredients counted for amount contributions meet the minimum criterion, which does not guarantee clinical benefit.
Impact
High effect
Vitamin K · 100 mcgVitamin D · 62.5 mcg
Vitamin K as explicitly identified MK-7 has limited evidence for selected arterial-stiffness measures, including a long trial in healthy postmenopausal women. That finding does not establish prevention of cardiovascular events. The serving provides a partial comparison exposure, while vitamin D does not establish an added cardiovascular benefit or a D3/K2 combination effect.
How this product is rated for Cardiovascular Support
Ingredient fit83
Vitamin K leads the relevant ingredient finding. The counted ingredients provide partial exposure coverage.
Goal fit
Vitamin K provides a focused connection to the selected cardiovascular aspects.
Dose adequacy
Vitamin K and other counted ingredients provide partial exposure coverage; this comparison does not predict the size of a benefit.
Pathways19
The strongest supplied connection is arterial calcification control. These assigned mechanisms concern selected markers, rather than proven cardiovascular-event prevention.
Depth
The strongest connection is arterial calcification control, reflecting declared amounts and assigned ingredient roles.
Breadth
No mechanism reaches the supplied coverage threshold.
Evidence69
Vitamin K leads the evidence finding, with the population and marker limits of its supplied research. Qualifying preparation declarations meet the supplied criteria.
Evidence strength
MK-7 findings concern selected arterial-stiffness measures, mainly in postmenopausal women.
Studied preparation
The qualifying ingredient declarations meet the supplied preparation criteria; matching does not establish personal applicability or a clinical-event benefit.
Formulation logic100
No unmet partner requirement or specified formulation conflict was identified. Clearing the exposure threshold does not establish a clinically effective cardiovascular dose.
Partner coverage
The counted ingredients work without an additional required partner or have that partner present.
Conflicts
No specified formulation conflict was matched in the supplied product facts.
Effective doses
All counted ingredients clear the minimum exposure threshold, without establishing a clinically effective cardiovascular dose.
Impact
High effect
Vitamin K · 100 mcgVitamin D · 62.5 mcg
MenaQ7 vitamin K2 has findings for selected measures of arterial stiffness in postmenopausal women over three years. The 100 mcg per serving is below the studied 180 mcg daily exposure, and some findings depended on high initial stiffness. Vitamin D can support muscle strength when deficiency is corrected. These findings do not establish a combined D3/K2 advantage or broader lifespan benefit.
How this product is rated for Longevity
Ingredient fit85
The ingredient mix and amounts give a focused match to the saved findings. Ingredient roles must still be interpreted within their specific human findings.
Goal fit
The formula is focused on its included ingredient, although its stated uses extend beyond aging.
Dose adequacy
The declared amounts largely support the saved comparison, although some contributions remain below their reference amounts.
Pathways42
The contribution centers on one pathway, with limited breadth across other aging-related processes.
Depth
Arterial calcification control is the strongest represented pathway. Its representation does not establish a clinical aging benefit.
Breadth
Only one reviewed pathway reaches the coverage threshold, limiting breadth across aging-related processes.
Evidence83
The saved evidence finding recognizes the included ingredient forms and amounts. The supplied human context supports only specific outcomes or correction of low intake, rather than general aging reversal.
Evidence strength
Vitamin D supplies the strongest saved evidence finding here; the specific population and outcome limits still apply.
Studied preparation
The included forms meet the saved preparation comparison. This does not extend their findings to general anti-aging effects.
Formulation logic100
The formula has no identified evaluated conflict, and partner requirements are met. The counted amounts meet the saved threshold without establishing a combined benefit.
Partner coverage
The included ingredients can contribute alone or have their required partner; no added benefit from combining them is established.
Conflicts
No evaluated ingredient conflict was identified in the supplied findings.
Effective doses
The counted ingredients meet the saved amount threshold, which is not a proven minimum dose for anti-aging benefits.
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Vitamin D-3 (Lanolin) | 62.5 mcg | |
Vitamin K-2 (Menaquinone-7) | 100 mcg |
Vitamin K (Menaquinone-7) · 100 mcg OverallScore93
Each serving provides 100 mcg of vitamin K2 as MK-7. MK-7 remains in the bloodstream longer than other common vitamin K forms.
How this ingredient is rated
Active Ingredient Quality & Bioavailability82
Menaquinone-7, or MK-7, is a form of vitamin K2 that stays in the bloodstream longer than other common forms.
Vitamin K Form (MK-7 vs. MK-4 vs. K1)
Menaquinone-7, or MK-7, is a form of vitamin K2 that stays in the bloodstream longer than other common forms.
MK-7 Isomer Disclosure
MK-7 is identified, but a trans or all-trans isomer is not specified in the saved facts.
Dose, Safety & Label Transparency100
The label identifies the form and states 100 mcg of MK-7 per serving.
Vitamin K2 (MK-7) Dosage Efficacy
Each serving provides 100 mcg of MK-7.
Form and Subtype Transparency
The label identifies MK-7 and states its amount as 100 mcg per serving.
Value100
A whole-product serving costs about $0.11.
Price per Effective MK-7 Serving
A whole-product serving costs about $0.11.
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Pregnancy vitamin D supplementation and offspring bone mineral density in childhood follow-up of a randomized controlled trial.
- Vitamin D analogs and bone: preclinical and clinical studies with eldecalcitol.
- Efficacy of vitamin D fortified foods on bone mineral density and serum bone biomarkers: A systematic review and meta-analysis of interventional studies.
- Cholecalciferol Supplementation Attenuates Bone Loss in Incident Kidney Transplant Recipients: A Prespecified Secondary Endpoint Analysis of a Randomized Controlled Trial.
- Vitamin D supplementation and bone health in post-menopausal women: a 24-month randomized controlled intervention with enhanced bioavailability formulations.
- Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials.
- Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women.
- Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis.
- Efficacy and safety of vitamin K2 for postmenopausal women with osteoporosis at a long-term follow-up: meta-analysis and systematic review.
- Low-dose vitamin K2 (MK-4) supplementation for 12 months improves bone metabolism and prevents forearm bone loss in postmenopausal Japanese women.
- Comparative Efficacy of Nutraceuticals on Endothelial Function: A Systematic Review and Network Meta-Analysis.
- A Randomized Trial of Vitamin D Supplementation on Vascular Function in CKD.
- Randomized, placebo-controlled, double-blind clinical trial on the contributions of vitamin D in the control of cardiovascular risk factors, depressive symptoms and suicide risk.
- Dose responses of vitamin D3 supplementation on arterial stiffness in overweight African Americans with vitamin D deficiency: A placebo controlled randomized trial.
- Paricalcitol and endothelial function in chronic kidney disease trial.
- Vitamin K Intake and Atherosclerotic Cardiovascular Disease in the Danish Diet Cancer and Health Study.
- Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial.
- Effects of One-Year Menaquinone-7 Supplementation on Vascular Stiffness and Blood Pressure in Post-Menopausal Women.
- Dietary Vitamin K1 Intake and Incident Aortic Valve Stenosis.
- Association between vitamin K1 intake and mortality in the Danish Diet, Cancer, and Health cohort.